All GlaxoSmithKline articles
-
Blog postSFO faces criticism for closing Rolls-Royce, GSK cases
The U.K. Serious Fraud Office closed two long-running bribery and corruption cases against Rolls-Royce and GlaxoSmithKline—a decision that casts further doubt around the effectiveness of the SFO’s investigatory powers and makes companies question the purpose of entering a deferred prosecution agreement at all.
-
Blog post
GlaxoSmithKline: An update on SFO investigation
GlaxoSmithKline isn’t out of the weeds yet. The pharmaceutical company this week said the U.K. Serious Fraud Office has requested new information relating to an ongoing investigation, this time concerning third-party advisers engaged by the company.
-
Blog post
Was the GlaxoSmithKline FCPA resolution a missed opportunity?
Tom Fox questions whether U.S. regulators missed a chance to illustrate how they would give credit for anti-corruption prosecutions done by other governments in the case of GlaxoSmithKline’s China subsidiary’s recent FCPA resolution.
